Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of CNP520 in healthy elderly
NCT02576639Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of umibecestat in Alzheimer's disease (AD) (5 arms), sponsored by Novartis. Primary endpoint: Number of Subjects With Non-serious and Serious Adverse Events (AEs) and Deaths at 13 weeks. Started Aug 2015; status: completed.
02
Drugs
umibecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02576639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576639.